PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Abir Salwa Ali; Seppo W Langer; Birgitte Federspiel; Geir Olav Hjortland; Henning Grønbæk; Morten Ladekarl; Staffan Welin; Lene Weber Vestermark; Johanna Arola; Pia Osterlund; Ulrich Knigge; Halfdan Sørbye; Patrick Micke; Lars Grimelius; Malin Grönberg; Eva Tiensuu Janson

doi:10.1371/journal.pone.0243900

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Abir Salwa Ali, Seppo W Langer, Birgitte Federspiel, Geir Olav Hjortland, Henning Grønbæk, Morten Ladekarl, Staffan Welin, Lene Weber Vestermark, Johanna Arola, Pia Osterlund, Ulrich Knigge, Halfdan Sørbye, Patrick Micke, Lars Grimelius, Malin Grönberg, Eva Tiensuu Janson

Research output: Contribution to journal › Journal article › Research › peer-review

12 Citations (Scopus)

48 Downloads (Pure)

Abstract

Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.

Original language	English
Article number	e0243900
Journal	PLOS ONE
Volume	15
Issue number	12
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0243900
Publication status	Published - 2020

Access to Document

10.1371/journal.pone.0243900Licence: CC BY 4.0

Ali et al. (2020) PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3Final published version, 2.84 MBLicence: CC BY 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Ali, A. S., Langer, S. W., Federspiel, B., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Welin, S., Weber Vestermark, L., Arola, J., Osterlund, P., Knigge, U., Sørbye, H., Micke, P., Grimelius, L., Grönberg, M., & Tiensuu Janson, E. (2020). PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLOS ONE, 15(12), Article e0243900. https://doi.org/10.1371/journal.pone.0243900

@article{bafcb81bf75c43ef88511c01608018c3,

title = "PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3",

abstract = "Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.",

author = "Ali, {Abir Salwa} and Langer, {Seppo W} and Birgitte Federspiel and Hjortland, {Geir Olav} and Henning Gr{\o}nb{\ae}k and Morten Ladekarl and Staffan Welin and {Weber Vestermark}, Lene and Johanna Arola and Pia Osterlund and Ulrich Knigge and Halfdan S{\o}rbye and Patrick Micke and Lars Grimelius and Malin Gr{\"o}nberg and {Tiensuu Janson}, Eva",

year = "2020",

doi = "10.1371/journal.pone.0243900",

language = "English",

volume = "15",

journal = "PLOS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "12",

}

Ali, AS, Langer, SW, Federspiel, B, Hjortland, GO, Grønbæk, H, Ladekarl, M, Welin, S, Weber Vestermark, L, Arola, J, Osterlund, P, Knigge, U, Sørbye, H, Micke, P, Grimelius, L, Grönberg, M & Tiensuu Janson, E 2020, 'PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3', PLOS ONE, vol. 15, no. 12, e0243900. https://doi.org/10.1371/journal.pone.0243900

TY - JOUR

T1 - PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

AU - Ali, Abir Salwa

AU - Langer, Seppo W

AU - Federspiel, Birgitte

AU - Hjortland, Geir Olav

AU - Grønbæk, Henning

AU - Ladekarl, Morten

AU - Welin, Staffan

AU - Weber Vestermark, Lene

AU - Arola, Johanna

AU - Osterlund, Pia

AU - Knigge, Ulrich

AU - Sørbye, Halfdan

AU - Micke, Patrick

AU - Grimelius, Lars

AU - Grönberg, Malin

AU - Tiensuu Janson, Eva

PY - 2020

Y1 - 2020

N2 - Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.

AB - Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.

U2 - 10.1371/journal.pone.0243900

DO - 10.1371/journal.pone.0243900

M3 - Journal article

C2 - 33315908

SN - 1932-6203

VL - 15

JO - PLOS ONE

JF - PLOS ONE

IS - 12

M1 - e0243900

ER -

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Abstract

Access to Document

AUB Link

Fingerprint

Cite this